APO Research
Talk to an analyst

APO RESEARCH · REPORT

Solid Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Solid Tumor Drug Industry Growth and Trends Forecast to 2032

27 December 2025102 pages

Choose your research edition.

Industry ResearchSolid Tumor Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Tumor Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Solid Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Tumor Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Tumor Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

According to APO Research, the global Solid Tumor Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Solid Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Solid Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Solid Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Solid Tumor Drug market include Johnson & Johnson, Pfizer Inc, GlaxoSmithKline plc., Baxter, AstraZeneca, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Celgene Corporation and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Solid Tumor Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Solid Tumor Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Solid Tumor Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Solid Tumor Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Solid Tumor Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Solid Tumor Drug Market by Company

Johnson & Johnson

Pfizer Inc

GlaxoSmithKline plc.

Baxter

AstraZeneca

F. Hoffmann-La Roche Ltd.

Eli Lilly and Company

Celgene Corporation

Bristol-Myers Squibb Company

Biogen

Amgen Limited & Amgen Ireland Limited

Abbott Laboratories

Solid Tumor Drug Segment by Type

Small Molecules

Biologics

Solid Tumor Drug Segment by Application

Radiology

Neurology

Oncology

Others

Solid Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Solid Tumor Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Solid Tumor Drug Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Solid Tumor Drug Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Solid Tumor Drug Market Share by Region (2021-2026) Table 4. Global Solid Tumor Drug Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Solid Tumor Drug Market Share by Region (2027-2032) Table 6. Global Solid Tumor Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Solid Tumor Drug Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Solid Tumor Drug Market Size Share by Type (2021-2026) Table 9. Global Solid Tumor Drug Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Solid Tumor Drug Market Size Share Forecasted by Type (2027-2032) Table 11. North America Solid Tumor Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Solid Tumor Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Solid Tumor Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Solid Tumor Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Solid Tumor Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Solid Tumor Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Solid Tumor Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Solid Tumor Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Solid Tumor Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Solid Tumor Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Solid Tumor Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Solid Tumor Drug Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Solid Tumor Drug Market Size Share by Application (2021-2026) Table 24. Global Solid Tumor Drug Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Solid Tumor Drug Market Size Share Forecasted by Application (2027-2032) Table 26. North America Solid Tumor Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Solid Tumor Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Solid Tumor Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Solid Tumor Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Solid Tumor Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Solid Tumor Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Solid Tumor Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Solid Tumor Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Solid Tumor Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Solid Tumor Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Solid Tumor Drug Industry Trends Table 37. Solid Tumor Drug Industry Drivers Table 38. Solid Tumor Drug Industry Opportunities and Challenges Table 39. Solid Tumor Drug Industry Restraints Table 40. Global Solid Tumor Drug Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Solid Tumor Drug Revenue Market Share by Company (2021-2026) Table 42. Global Solid Tumor Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Solid Tumor Drug Key Company Headquarters & Area Served Table 44. Global Solid Tumor Drug Company, Product Type & Application Table 45. Global Solid Tumor Drug Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Solid Tumor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Johnson & Johnson Company Information Table 49. Johnson & Johnson Business Overview Table 50. Johnson & Johnson Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Johnson & Johnson Solid Tumor Drug Product Portfolio Table 52. Johnson & Johnson Recent Development Table 53. Pfizer Inc Company Information Table 54. Pfizer Inc Business Overview Table 55. Pfizer Inc Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Pfizer Inc Solid Tumor Drug Product Portfolio Table 57. Pfizer Inc Recent Development Table 58. GlaxoSmithKline plc. Company Information Table 59. GlaxoSmithKline plc. Business Overview Table 60. GlaxoSmithKline plc. Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio Table 62. GlaxoSmithKline plc. Recent Development Table 63. Baxter Company Information Table 64. Baxter Business Overview Table 65. Baxter Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Baxter Solid Tumor Drug Product Portfolio Table 67. Baxter Recent Development Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. AstraZeneca Solid Tumor Drug Product Portfolio Table 72. AstraZeneca Recent Development Table 73. F. Hoffmann-La Roche Ltd. Company Information Table 74. F. Hoffmann-La Roche Ltd. Business Overview Table 75. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio Table 77. F. Hoffmann-La Roche Ltd. Recent Development Table 78. Eli Lilly and Company Company Information Table 79. Eli Lilly and Company Business Overview Table 80. Eli Lilly and Company Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Eli Lilly and Company Solid Tumor Drug Product Portfolio Table 82. Eli Lilly and Company Recent Development Table 83. Celgene Corporation Company Information Table 84. Celgene Corporation Business Overview Table 85. Celgene Corporation Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Celgene Corporation Solid Tumor Drug Product Portfolio Table 87. Celgene Corporation Recent Development Table 88. Bristol-Myers Squibb Company Company Information Table 89. Bristol-Myers Squibb Company Business Overview Table 90. Bristol-Myers Squibb Company Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio Table 92. Bristol-Myers Squibb Company Recent Development Table 93. Biogen Company Information Table 94. Biogen Business Overview Table 95. Biogen Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Biogen Solid Tumor Drug Product Portfolio Table 97. Biogen Recent Development Table 98. Amgen Limited & Amgen Ireland Limited Company Information Table 99. Amgen Limited & Amgen Ireland Limited Business Overview Table 100. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio Table 102. Amgen Limited & Amgen Ireland Limited Recent Development Table 103. Abbott Laboratories Company Information Table 104. Abbott Laboratories Business Overview Table 105. Abbott Laboratories Solid Tumor Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Abbott Laboratories Solid Tumor Drug Product Portfolio Table 107. Abbott Laboratories Recent Development Table 108. North America Solid Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. North America Solid Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 110. North America Solid Tumor Drug Market Share by Country (2021-2026) Table 111. North America Solid Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. North America Solid Tumor Drug Market Share Forecast by Country (2027-2032) Table 113. Europe Solid Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Europe Solid Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 115. Europe Solid Tumor Drug Market Share by Country (2021-2026) Table 116. Europe Solid Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Europe Solid Tumor Drug Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Solid Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Solid Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 120. Asia-Pacific Solid Tumor Drug Market Share by Country (2021-2026) Table 121. Asia-Pacific Solid Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Asia-Pacific Solid Tumor Drug Market Share Forecast by Country (2027-2032) Table 123. Latin America Solid Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Latin America Solid Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 125. Latin America Solid Tumor Drug Market Share by Country (2021-2026) Table 126. Latin America Solid Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Latin America Solid Tumor Drug Market Share Forecast by Country (2027-2032) Table 128. Middle East & Africa Solid Tumor Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Middle East & Africa Solid Tumor Drug Market Size by Country (2021-2026) & (US$ Million) Table 130. Middle East & Africa Solid Tumor Drug Market Share by Country (2021-2026) Table 131. Middle East & Africa Solid Tumor Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Middle East & Africa Solid Tumor Drug Market Share Forecast by Country (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Solid Tumor Drug Product Image Figure 3. Global Solid Tumor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Solid Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 5. Global Solid Tumor Drug Market Share by Region: 2025 VS 2032 Figure 6. Global Solid Tumor Drug Market Share by Region (2021-2032) Figure 7. North America Solid Tumor Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Solid Tumor Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Solid Tumor Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Solid Tumor Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Solid Tumor Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Small Molecules Image Figure 13. Global Small Molecules Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Biologics Image Figure 15. Global Biologics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Solid Tumor Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Solid Tumor Drug Market Share by Type 2025 VS 2032 Figure 18. North America Solid Tumor Drug Market Size Share by Type (2021-2032) Figure 19. Europe Solid Tumor Drug Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Solid Tumor Drug Market Size Share by Type (2021-2032) Figure 21. Latin America Solid Tumor Drug Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Solid Tumor Drug Market Size Share by Type (2021-2032) Figure 23. Radiology Image Figure 24. Global Radiology Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Neurology Image Figure 26. Global Neurology Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Oncology Image Figure 28. Global Oncology Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Others Image Figure 30. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Solid Tumor Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Solid Tumor Drug Market Share by Application 2025 VS 2032 Figure 33. North America Solid Tumor Drug Market Size Share by Application (2021-2032) Figure 34. Europe Solid Tumor Drug Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Solid Tumor Drug Market Size Share by Application (2021-2032) Figure 36. Latin America Solid Tumor Drug Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Solid Tumor Drug Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Solid Tumor Drug Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Solid Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Solid Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Solid Tumor Drug Market Share by Country (2021-2032) Figure 43. Europe Solid Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Solid Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Solid Tumor Drug Market Share by Country (2021-2032) Figure 46. Asia-Pacific Solid Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Solid Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Solid Tumor Drug Market Share by Country (2021-2032) Figure 49. Latin America Solid Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Solid Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Solid Tumor Drug Market Share by Country (2021-2032) Figure 52. Middle East & Africa Solid Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Solid Tumor Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Solid Tumor Drug Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecules
  • Biologics
Applications
  • Radiology
  • Neurology
  • Oncology
  • Others
Companies covered
  • Johnson & Johnson
  • Pfizer Inc
  • GlaxoSmithKline plc.
  • Baxter
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • Biogen
  • Amgen Limited & Amgen Ireland Limited
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Solid Tumor Drug Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Solid Tumor Drug Market Size by Region (2021-2032)
  5. 1.4.1 Global Solid Tumor Drug Market Size by Region (2021-2026)
  6. 1.4.2 Global Solid Tumor Drug Market Size by Region (2027-2032)
  7. 1.5 Key Regions Solid Tumor Drug Market Size (2021-2032)
  8. 1.5.1 North America Solid Tumor Drug Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Solid Tumor Drug Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Solid Tumor Drug Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Solid Tumor Drug Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Solid Tumor Drug Market Size Growth Rate (2021-2032)
2 Solid Tumor Drug Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Small Molecules
  3. 2.1.2 Biologics
  4. 2.2 Global Solid Tumor Drug Market Size by Type
  5. 2.2.1 Global Solid Tumor Drug Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Solid Tumor Drug Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Solid Tumor Drug Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Solid Tumor Drug Market Size by Regions
  9. 2.3.1 North America Solid Tumor Drug Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Solid Tumor Drug Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Solid Tumor Drug Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Solid Tumor Drug Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Solid Tumor Drug Market Size Breakdown by Type (2021-2026)
3 Solid Tumor Drug Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Radiology
  3. 3.1.2 Neurology
  4. 3.1.3 Oncology
  5. 3.1.4 Others
  6. 3.2 Global Solid Tumor Drug Market Size by Application
  7. 3.2.1 Global Solid Tumor Drug Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global Solid Tumor Drug Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global Solid Tumor Drug Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global Solid Tumor Drug Market Size by Regions
  11. 3.3.1 North America Solid Tumor Drug Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe Solid Tumor Drug Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific Solid Tumor Drug Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America Solid Tumor Drug Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa Solid Tumor Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Solid Tumor Drug Industry Trends
  2. 4.2 Solid Tumor Drug Industry Drivers
  3. 4.3 Solid Tumor Drug Industry Opportunities and Challenges
  4. 4.4 Solid Tumor Drug Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Solid Tumor Drug Revenue (2021-2026)
  2. 5.2 Global Solid Tumor Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Solid Tumor Drug Key Company Headquarters & Area Served
  4. 5.4 Global Solid Tumor Drug Company, Product Type & Application
  5. 5.5 Global Solid Tumor Drug Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Solid Tumor Drug Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Solid Tumor Drug Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Solid Tumor Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Johnson & Johnson
  2. 6.1.1 Johnson & Johnson Company Information
  3. 6.1.2 Johnson & Johnson Business Overview
  4. 6.1.3 Johnson & Johnson Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Johnson & Johnson Solid Tumor Drug Product Portfolio
  6. 6.1.5 Johnson & Johnson Recent Developments
  7. 6.2 Pfizer Inc
  8. 6.2.1 Pfizer Inc Company Information
  9. 6.2.2 Pfizer Inc Business Overview
  10. 6.2.3 Pfizer Inc Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer Inc Solid Tumor Drug Product Portfolio
  12. 6.2.5 Pfizer Inc Recent Developments
  13. 6.3 GlaxoSmithKline plc.
  14. 6.3.1 GlaxoSmithKline plc. Company Information
  15. 6.3.2 GlaxoSmithKline plc. Business Overview
  16. 6.3.3 GlaxoSmithKline plc. Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio
  18. 6.3.5 GlaxoSmithKline plc. Recent Developments
  19. 6.4 Baxter
  20. 6.4.1 Baxter Company Information
  21. 6.4.2 Baxter Business Overview
  22. 6.4.3 Baxter Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Baxter Solid Tumor Drug Product Portfolio
  24. 6.4.5 Baxter Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca Solid Tumor Drug Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 F. Hoffmann-La Roche Ltd.
  32. 6.6.1 F. Hoffmann-La Roche Ltd. Company Information
  33. 6.6.2 F. Hoffmann-La Roche Ltd. Business Overview
  34. 6.6.3 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio
  36. 6.6.5 F. Hoffmann-La Roche Ltd. Recent Developments
  37. 6.7 Eli Lilly and Company
  38. 6.7.1 Eli Lilly and Company Company Information
  39. 6.7.2 Eli Lilly and Company Business Overview
  40. 6.7.3 Eli Lilly and Company Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Eli Lilly and Company Solid Tumor Drug Product Portfolio
  42. 6.7.5 Eli Lilly and Company Recent Developments
  43. 6.8 Celgene Corporation
  44. 6.8.1 Celgene Corporation Company Information
  45. 6.8.2 Celgene Corporation Business Overview
  46. 6.8.3 Celgene Corporation Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Celgene Corporation Solid Tumor Drug Product Portfolio
  48. 6.8.5 Celgene Corporation Recent Developments
  49. 6.9 Bristol-Myers Squibb Company
  50. 6.9.1 Bristol-Myers Squibb Company Company Information
  51. 6.9.2 Bristol-Myers Squibb Company Business Overview
  52. 6.9.3 Bristol-Myers Squibb Company Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio
  54. 6.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 6.10 Biogen
  56. 6.10.1 Biogen Company Information
  57. 6.10.2 Biogen Business Overview
  58. 6.10.3 Biogen Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Biogen Solid Tumor Drug Product Portfolio
  60. 6.10.5 Biogen Recent Developments
  61. 6.11 Amgen Limited & Amgen Ireland Limited
  62. 6.11.1 Amgen Limited & Amgen Ireland Limited Company Information
  63. 6.11.2 Amgen Limited & Amgen Ireland Limited Business Overview
  64. 6.11.3 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio
  66. 6.11.5 Amgen Limited & Amgen Ireland Limited Recent Developments
  67. 6.12 Abbott Laboratories
  68. 6.12.1 Abbott Laboratories Company Information
  69. 6.12.2 Abbott Laboratories Business Overview
  70. 6.12.3 Abbott Laboratories Solid Tumor Drug Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Abbott Laboratories Solid Tumor Drug Product Portfolio
  72. 6.12.5 Abbott Laboratories Recent Developments
7 North America
  1. 7.1 North America Solid Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Solid Tumor Drug Market Size by Country (2021-2026)
  3. 7.3 North America Solid Tumor Drug Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Solid Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Solid Tumor Drug Market Size by Country (2021-2026)
  3. 8.3 Europe Solid Tumor Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Solid Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Solid Tumor Drug Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Solid Tumor Drug Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Solid Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Solid Tumor Drug Market Size by Country (2021-2026)
  3. 10.3 South America Solid Tumor Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Solid Tumor Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Solid Tumor Drug Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Solid Tumor Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst